Cargando…

Impacts of anti‐inflammatory phosphodiesterase inhibitors on a murine model of chronic pulmonary inflammation

Chronic obstructive pulmonary disease (COPD) often tends to respond poorly to glucocorticoid (GC) therapy. Reduced Histone deacetylase‐2 (HDAC‐2) activity is an important mechanism behind this GC insensitivity. In this study, we investigated the effects of three phosphodiesterase inhibitors (PDEIs),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Xiao‐Fang, Chen, Dan‐Dan, Zhu, Xiao‐Ling, Le Grange, Jehane Michael, Zhou, Lu‐Qian, Zhang, Jin‐Nong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322673/ https://www.ncbi.nlm.nih.gov/pubmed/34327862 http://dx.doi.org/10.1002/prp2.840

Ejemplares similares

Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
por: Rhee, Chin Kook, et al.
Publicado: (2020)

Natural Phosphodiesterase-4 Inhibitors with Potential Anti-Inflammatory Activities from Millettia dielsiana
por: Le, Vu Thi Thu, et al.
Publicado: (2023)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients
por: Lan, Wei-Fang, et al.
Publicado: (2022)

The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
por: Butrous, Ghazwan
Publicado: (2014)

The Unrecognized Effects of Phosphodiesterase 4 on Epithelial Cells in Pulmonary Inflammation
por: Konrad, Franziska M., et al.
Publicado: (2015)

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells
por: Grundy, Seamus, et al.
Publicado: (2016)

0997. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation
por: Konrad, F, et al.
Publicado: (2014)

Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
por: Luo, Jian, et al.
Publicado: (2016)

Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model
por: Kagitani-Shimono, Kuriko, et al.
Publicado: (2005)

Phosphodiesterases Expression during Murine Cardiac Development
por: Carvalho, Thays Maria da Conceição Silva, et al.
Publicado: (2021)

The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma
por: Clayton, Robert A, et al.
Publicado: (2004)

Coinfection of SARS-CoV-2 and Other Respiratory Pathogens
por: Ma, Ling, et al.
Publicado: (2020)

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy
por: Buckley, Mitchell S, et al.
Publicado: (2010)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines
por: Edwards, Michael R., et al.
Publicado: (2016)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?
por: Goonathilake, Mastiyage R, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Effects of phosphodiesterase 3A modulation on murine cerebral microhemorrhages
por: Sumbria, Rachita K., et al.
Publicado: (2017)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016)

New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021)

Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism
por: Sharma, Munish, et al.
Publicado: (2019)

Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry
por: Garcia, Agustin R., et al.
Publicado: (2023)

Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review)
por: Su, Hao, et al.
Publicado: (2021)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy
por: Wen, Jian-jun, et al.
Publicado: (2016)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

Effect and Mechanism of Phosphodiesterase Inhibitors on Trabecular Outflow
por: Kim, Jae Woo, et al.
Publicado: (2019)

Additive Effect of Phosphodiesterase Inhibitors in Control of Pulmonary Hypertension after Congenital Cardiac Surgery in Children
por: Peiravian, Farah, et al.
Publicado: (2013)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e5g73c8n1r9eahcbbm6pvem1fc